Albert Einstein College of Medicine

Vascarta Inc. announced that the FDA has granted Orphan Drug Designation to Vasceptor (VAS-101), a patented topical curcumin formulation for treating Sickle Cell Disease.

Genflow Biosciences has successfully progressed its SIRT6 variant patent application through the European Patent Office's Supplementary Search Report without additional questions, strengthening its intellectual property position.

HCW Biologics' proprietary fusion protein HCW9206 demonstrates superior efficacy in generating CAR-T cells with enhanced function and persistence compared to standard methods.

A groundbreaking clinical trial demonstrates that fremanezumab, a CGRP-targeting monoclonal antibody, significantly reduces both migraine frequency and depressive symptoms in patients with comorbid conditions.

Delayed REM sleep is associated with higher levels of toxic brain proteins linked to Alzheimer's disease, with late-onset REM showing 16% more amyloid and 29% more tau protein compared to early-onset REM.

Vascarta has initiated a Phase 1 proof-of-concept study evaluating VAS-101, a novel topical curcumin formulation, in ten patients with sickle cell disease at the Foundation for Sickle Cell Disease Research in Florida.

Researchers found that tumor mutational burden (TMB) and fraction genome altered (FGA) can predict how anesthetic and analgesic drugs affect survival in cancer patients.

The NIH has developed TrialGPT, an AI algorithm designed to efficiently match patients to relevant clinical trials listed on ClinicalTrials.gov.

The TAME Trial will investigate metformin's potential to prevent age-related diseases like heart disease, cancer, and cognitive decline in healthy older adults.

• The TAME trial aims to demonstrate that metformin, a drug approved for diabetes, can delay multiple age-related diseases like cardiovascular disease, cancer, and cognitive decline. • Nir Barzilai's TAME trial received FDA agreement in 2015 but has struggled to secure the $30-50 million needed, as philanthropists favor 'moonshot' projects over repurposing generic drugs. • Experts believe the TAME trial could establish a framework for biotech companies, proving that targeting aging is a viable strategy for preventing multiple diseases simultaneously. • Barzilai is now seeking funding from crypto-millionaires and Hevolution, hoping to launch the trial and establish aging as an indication for drug approval.